Search by Drug Name or NDC
NDC 69238-1250-01 Bexarotene 75 mg/1 Details
Bexarotene 75 mg/1
Bexarotene is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Amneal Pharmaceuticals NY LLC. The primary component is BEXAROTENE.
MedlinePlus Drug Summary
Bexarotene is used to treat cutaneous T-cell lymphoma (CTCL, a type of skin cancer) in people whose disease could not be treated successfully with at least one other medication. Bexarotene is in a class of medications called retinoids. It works by stopping the growth of cancer cells.
Related Packages: 69238-1250-01Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Bexarotene
Product Information
| NDC | 69238-1250 |
|---|---|
| Product ID | 69238-1250_9e70a6ae-538e-406a-9814-a0a21121ba3d |
| Associated GPIs | 21708220000120 |
| GCN Sequence Number | 044269 |
| GCN Sequence Number Description | bexarotene CAPSULE 75 MG ORAL |
| HIC3 | V1N |
| HIC3 Description | ANP - SELECTIVE RETINOID X RECEPTOR AGONISTS (RXR) |
| GCN | 92373 |
| HICL Sequence Number | 020832 |
| HICL Sequence Number Description | BEXAROTENE |
| Brand/Generic | Generic |
| Proprietary Name | Bexarotene |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Bexarotene |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 75 |
| Active Ingredient Units | mg/1 |
| Substance Name | BEXAROTENE |
| Labeler Name | Amneal Pharmaceuticals NY LLC |
| Pharmaceutical Class | Retinoid [EPC], Retinoids [CS] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA210105 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 69238-1250-01 (69238125001)
| NDC Package Code | 69238-1250-1 |
|---|---|
| Billing NDC | 69238125001 |
| Package | 1 BOTTLE in 1 CARTON (69238-1250-1) / 100 CAPSULE in 1 BOTTLE |
| Marketing Start Date | 2018-09-04 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |